Knight Therapeutics Inc. Announces Approval of Halaven® in Colombia
Biz Wire Express,
GlobeNewswire 2022-01-06 MONTREAL, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc.
GlobeNewswire 2022-01-06 MONTREAL, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc.
MONTREAL, Jan. 06, 2022 (GLOBE NEWSWIRE) -- (TSX:GUD) (“Knight” or “the Company”) announced today that its Colombian affiliate…
MONTREAL, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) announced today that…
Halaven® (eribulin) injection is indicated for the treatment of adult patients with locally advanced or metastatic breast…